ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Lundbeck, Otsuka Link For Psychiatric Drugs

by Michael McCoy
November 21, 2011 | APPEARED IN VOLUME 89, ISSUE 47

Denmark’s Lundbeck and Japan’s Otsuka have formed an alliance that plans to deliver up to five new psychiatric drugs. Under the deal, Lundbeck will share rights to develop and commercialize a long-acting form of Otsuka’s aripiprazole, sold as Abilify, and an Otsuka psychotherapeutic now in Phase III clinical trials. Otsuka has an option to share development and commercialization of three Lundbeck drugs that are in the early stages of development. Under the deal, Lundbeck will pay Otsuka $200 million up front and as much as $1.4 billion in milestone payments.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment